Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Frequently asked questions
What sector does Sensorion SA (ALSEN) operate in?
Sensorion SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Sensorion SA (ALSEN) current stock price?
As of the latest data, Sensorion SA stock price is €0.29, with a previous close of €0.29.
What is Sensorion SA (ALSEN) current market capitalization?
Sensorion SA market cap is approximately 148.93 million.
What is Sensorion SA (ALSEN) Earnings Per Share (EPS)?
The trailing EPS is -€0.10, and the forward EPS is -€0.05.
Does Sensorion SA (ALSEN) pay dividends?
No. Sensorion SA does not pay a dividend.
What is Sensorion SA (ALSEN) beta (volatility) score?
Sensorion SA has a beta of 0.417, indicating lower volatility than the overall market.
